A randomized, double‐blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short‐ and long‐term efficacy and safety results
Nicolino Ruperto(Istituto Giannina Gaslini), Stefan Simianer(Boehringer Ingelheim (Germany)), Eileen Baildam(Alder Hey Children's NHS Foundation Trust), Ynessa Shachbazian(Sechenov University), Ivan Foeldvari(Center for Rheumatology), Antonella Buoncompagni(Istituto Giannina Gaslini), Alberto Martini(Agenzia Regionale Prevenzione e Ambiente della Regione Emilia-Romagna), Richard Mouy(Hôpital Necker-Enfants Malades), Isabelle Koné‐Paut(Université Paris-Saclay), Ralf Sigmund(Boehringer Ingelheim (Germany)), Márcia Bandeira(Istituto Giannina Gaslini), Gertraud Hanft(Boehringer Ingelheim (Germany)), Francesco Zulian(University of Padua), В. А. Артамонова(Russian Children's Clinical Hospital), Evgueni D. Pachanov(Scientific Center of Children's Health), Maria Alessio(University of Naples Federico II), И. П. Никишина(Association of Rheumatologists of Russia), Rik Joos(Ghent University Hospital), Fernanda Falcini(University of Florence), A M Prieur(Hôpital Necker-Enfants Malades), Rudolf Schwarz(Universität Hamburg), V. Gerloni(Istituto Ortopedico Gaetano Pini), Wolfgang Emminger, A. Lenhardt(IRCCS Materno Infantile Burlo Garofolo)
Cited by 97
Related Papers
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
|Frontiers in Pharmacology|2019|616